

Stephen M. Fox

Associate

Berwyn stephen.fox@troutman.com D 610.640.7845



OVERVIEW

Stephen is an associate in the firm's Corporate practice, resident in the Berwyn office. Stephen advises public and private pharmaceutical, biotechnology, and medical device companies in a broad range of matters, including mergers and acquisitions, joint ventures, divestitures, capital markets transactions, Securities Exchange Act reporting, corporate governance, licensing and collaboration transactions and other strategic transactions. He also represents venture capital and seed-stage investors, emerging companies and entrepreneurs in formations, equity and debt financings, as well as other ongoing strategic matters.

AWARDS

• Best Lawyers in America®: Ones to Watch, Life Sciences Practice (2026), Mergers and Acquisitions Law (2026), Venture Capital Law (2026)

TOP AREAS OF FOCUS

- Corporate
- Emerging Companies + Venture Capital

ALL AREAS OF FOCUS

- Capital Markets
- Corporate
- Emerging Companies + Venture Capital
- Health Care + Life Sciences
- Life Sciences Transactions

EDUCATION AND CERTIFICATIONS

EDUCATION

- Boston University School of Law, J.D., 2016, article editor, Journal of Science & Technology Law
- Syracuse University, M.S., 2012, Entrepreneurship and Emerging Enterprises, Kauffman Entrepreneurship Engagement Fellow
- Syracuse University, B.S., 2011, communications

BAR ADMISSIONS

- Massachusetts
- Pennsylvania

LANGUAGES

• Hebrew (basic)

PUBLICATIONS

- Co-author, "2025 SCOPE Conference Emphasizes Al and Better Technologies to Improve Patient Outcomes," Troutman Pepper Locke, February 11, 2025.
- Co-author, "Private Equity Consolidation of Physician Practices Steady Despite Economic Conditions," Troutman Pepper, July 8, 2024.
- Co-author, "Ready for the Biotech Bounce Back in 2024?," Troutman Pepper, March 14, 2024.